Stock Blog Hub » Diagnostic Substances

(ABAX) Abaxis Analyst Upgrades Shares to Neutral

vitalstocks — Thu, 01 Dec 2011 15:16:51 +0000

Following the company’s solid second quarter 2011 results, which were ahead of the Zacks Consensus Estimates, we have upgraded our recommendation on Abaxis (ABAX) to Neutral with a target price of $26.00. The company reported EPS of 15 cents in the quarter, surpassing the Zacks Consensus Estimate by 2 cents. On the other hand, net [...]

(ABAX) Abaxis Analyst Upgrades Shares to Neutral

(ABAX) Alere Takes Over Arriva Medical

vitalstocks — Thu, 01 Dec 2011 15:15:27 +0000

Alere (ALR), a medical products company focused on integrating rapid diagnostics with health management, recently revealed that it has taken over Arriva Medical, a prominent vendor of diabetes testing supplies for patients residing at home. Florida-based Arriva had sales of about $21.5 million for the half year ending October 31, 2011. The company delivers diabetes [...]

(ABAX) Alere Takes Over Arriva Medical

(SRDX) SurModics Analysts Cut Shares to Neutral

vitalstocks — Sun, 10 Jul 2011 18:17:57 +0000

We are downgrading SurModics (SRDX) to Neutral from Outperform following its setback, when partner Johnson & Johnson (JNJ) announced in June 2011 that it will stop manufacturing Cypher and Cypher Select Plus sirolimus-eluting coronary stents by year-end. SurModics receives royalties on sales of the product. The news impacted SurModics’ shares negatively. We too have slashed [...]

(SRDX) SurModics Analysts Cut Shares to Neutral

(BLUD) Company News for July 6, 2011 – Corporate Summary

vitalstocks — Wed, 06 Jul 2011 15:47:24 +0000

• Share prices of Southern Union Co. (NYSE:SUG) rose 4.21% to close at $42.07 after Energy Transfer Equity, L.P. (NYSE:ETE) increased its bidding amount by 21% to $5 billion for the company, beating William’s (NYSE:WMB) bid of $4.9 billion • U.S. mining giant Peabody Energy Corp. (NYSE:BTU) was amongst a consortium selected by the Mongolian [...]

(BLUD) Company News for July 6, 2011 – Corporate Summary

(BLUD) Immucor Purchased by TPG Capital for $1.9B

vitalstocks — Wed, 06 Jul 2011 15:45:46 +0000

Manufacturer and seller of automated systems and reagents, Immucor Inc. (BLUD) recently announced that it will be taken over by private equity group TPG Capital for $1.97 billion. As per the terms of the agreement, Immucor’s shareholders will receive $27 in cash for each share of the company, representing a premium of 30.2% over the [...]

(BLUD) Immucor Purchased by TPG Capital for $1.9B

(MYGN) Myriad Genetics Analyst Uprades Shares to Outperform

vitalstocks — Fri, 01 Jul 2011 16:39:43 +0000

Recently, we upgraded Myriad Genetics (MYGN) to Outperform with a target price of $27.00. Myriad is confident of retaining the momentum recorded over the past few quarters going ahead through product portfolio expansion, targeting the companion diagnostic market and expansion into Europe. With respect to new products, Myriad aims to launch at least one new [...]

(MYGN) Myriad Genetics Analyst Uprades Shares to Outperform

(MYGN) Myriad Genetics – Bull of the Day

vitalstocks — Fri, 01 Jul 2011 16:39:03 +0000

Myriad Genetics’ (MYGN) flagship product, Bracanalysis, has been recording robust growth over the past few quarters. Moreover, the company is undertaking strategies to expand the scope of the test. A strong cash balance enables the company to buyback shares, expand into new markets and introduce more products. Moreover, the acquisition of RMB will help diversify [...]

(MYGN) Myriad Genetics – Bull of the Day

(DDD) 3D Printing Comes of Age

InvestmentU — Mon, 27 Jun 2011 15:15:35 +0000

by Ryan Cole, Investment U Research Analyst Monday, June 27, 2011 Yet again science fiction is becoming science fact. This time, it’s the Star Trek replicator. Granted – we don’t have the technology to rearrange molecules as we wish yet, as they do on the USS Enterprise. Still – the 3D printer comes close. As [...]

(DDD) 3D Printing Comes of Age

(AMAG) AMAG Pharmaceuticals Gets Label Update for Feraheme

vitalstocks — Sun, 26 Jun 2011 16:41:13 +0000

AMAG Pharmaceuticals Inc. (AMAG) recently announced a label update for its lead drug Feraheme. Feraheme is an injectable drug for intravenous use as an iron replacement therapy for the treatment of iron deficiency anemia (IDA) in adult patients suffering from chronic kidney disease (CKD). The label was updated following approval by the US Food and [...]

(AMAG) AMAG Pharmaceuticals Gets Label Update for Feraheme

(SRDX) SurModics Incorporated – Bull of the Day

vitalstocks — Tue, 21 Jun 2011 13:25:16 +0000

In June 2011, SurModics, Inc. (SRDX) received a blow when Johnson & Johnson announced that it will stop manufacturing Cypher stents by year end, as SurModics receives royalties on sales of the product. However, we believe the impact of the blow will not be very severe, and that the current price represents an attractive entry [...]

(SRDX) SurModics Incorporated – Bull of the Day

(AKRX) Company News for June 07, 2011 – Corporate Summary

vitalstocks — Tue, 07 Jun 2011 16:57:19 +0000

• Share prices of home nursing provider Amedisys, Inc.(NASDAQ:AMED) fell 7.41% after CRT Capital reduced its earnings estimates for fiscal 2011 • According to Canaccord Genuity, data from a trial of Exelixis, Inc’s (NASDAQ:EXEL) cancer-drug candidate could possibly worsen its regulatory strategy • According to the Wall Street Journal, Novartis AG (NYSE:NVS) could possibly opt [...]

(AKRX) Company News for June 07, 2011 – Corporate Summary

(VIVO) FDA OKs Meridian C. Difficile Test

vitalstocks — Fri, 13 May 2011 20:25:43 +0000

Diagnostic test kit maker Meridian Bioscience (VIVO) has clinched the approval of U.S. Food and Drug Administration (“FDA”) for its new C. difficile (Clostridium difficile) test dubbed Premier C. difficile GDH. The approval of this next-generation test broadens the Cincinnati-based company’s portfolio of C. difficile tests and underscores its sustained commitment to bring out breakthrough [...]

(VIVO) FDA OKs Meridian C. Difficile Test

(ABAX) Alere Quarterly Earnings Beats Estimates

vitalstocks — Wed, 04 May 2011 17:04:16 +0000

Alere (ALR), a medical products company focused on integrating rapid diagnostics with health management, reported first-quarter fiscal 2011 adjusted earnings per share of 61 cents, beating the corresponding Zacks Consensus Estimate of 57 cents while trailing the year-ago earnings from continuing operations of 64 cents a share. Reported net income was about $8.1 million (or [...]

(ABAX) Alere Quarterly Earnings Beats Estimates

(SRDX) SurModics Analyst Increases Shares to Outperform

vitalstocks — Wed, 04 May 2011 16:49:51 +0000

We are upgrading SurModics Inc. (SRDX) to Outperform from Neutral following its strong showing in the second quarter of fiscal 2011. Our target price on the stock is $18.00. The company delivered strong results in the second quarter of fiscal 2011 outshining the Zacks Consensus Estimate on both revenues and earnings fronts. Adjusted earnings in [...]

(SRDX) SurModics Analyst Increases Shares to Outperform

(SRDX) SurModics Incorporated – Bull of the Day

vitalstocks — Wed, 04 May 2011 16:40:22 +0000

We are upgrading SurModics Inc. (SRDX) to Outperform from Neutral following its strong showing in the second quarter of fiscal 2011. Adjusted earnings in the quarter came in at $0.08 per share, well ahead of break-even earnings suggested by the Zacks Consensus Estimate. Following the strong showing, the company raised its revenues and earnings projections [...]

(SRDX) SurModics Incorporated – Bull of the Day

(PBIO) Pressure BioSciences and KeraFAST Sign Worldwide E-Commerce Distribution Deal

vitalstocks — Tue, 03 May 2011 18:11:37 +0000

Grant Zeng, CFA PBIO and KeraFAST Sign Worldwide E-Commerce Distribution Deal On May 3, 2011, Pressure BioSciences, Inc. (PBIO) and KeraFAST LLC announced that they have entered into a non-exclusive, worldwide distribution agreement covering several of PBIO’s new sample preparation products. These products include the recently released The SHREDDER SG3 Extraction System; the novel MicroTube, [...]

(PBIO) Pressure BioSciences and KeraFAST Sign Worldwide E-Commerce Distribution Deal

(MYGN) Myriad Genetics and BioMarin Pharmaceuticals Enter Agreement for Testing

vitalstocks — Sat, 09 Apr 2011 19:13:47 +0000

Myriad Genetics (MYGN) has entered into an agreement with BioMarin Pharmaceuticals (BMRN) to conduct BRCA1 and BRCA2 mutation testing on patients to be enrolled in the latter’s phase I/II clinical study of BMN 673. BMN 673 is a PARP-inhibitor drug candidate for treatment of genetically defined cancers. Bracanalysisis Myriad’s flagship product, contributing 89% of total [...]

(MYGN) Myriad Genetics and BioMarin Pharmaceuticals Enter Agreement for Testing

(TRIB) Trinity Biotech – Bull of the Day

vitalstocks — Thu, 17 Mar 2011 17:05:40 +0000

Since its Q2 2010 clinical lab coag divestiture, Trinity Biotech (TRIB) has slashed operating costs and begun pumping its huge and growing cash balance into higher growth segments. Expectations are high for the PDX instrument, expected to launch in Europe and the U.S. in 2011. Development of several new POC tests is ongoing, the fruits [...]

(TRIB) Trinity Biotech – Bull of the Day

vitalstocks — Sun, 13 Mar 2011 18:49:56 +0000

(TRIB) Trinity Biotech – Bull of the Day

(SRDX) SurModics Analyst Maintains Neutral Rating on Shares

vitalstocks — Tue, 14 Sep 2010 13:16:25 +0000

SurModics (SRDX), headquartered in Eden Prairie, Minnesota, is a provider of surface modification and drug delivery technologies to the healthcare industry. Following the changes in operational structure affected in 2008, the company currently operates through the following business units: cardiovascular, ophthalmology, SurModics pharmaceuticals (constituting the “therapeutic” segment) and In Vitro Technologies (diagnostics). Surmodics performed disappointingly [...]

(SRDX) SurModics Analyst Maintains Neutral Rating on Shares

(SRDX) SurModics Signs Deal With Australian company Clinuvel Pharmaceuticals

vitalstocks — Sun, 11 Jul 2010 14:21:16 +0000

Recently, SurModics Inc. (SRDX) inked a licensing deal with Australian company Clinuvel Pharmaceuticals Limited. The deal allows SurModics’ pharmaceuticals unit, which provides proprietary polymer-based drug delivery technologies to companies developing advanced pharmaceutical products, to license some of its biodegradable polymer implant technology to the Melbourne-based company. The technology is used for treating sun-induced skin disorders. [...]

(SRDX) SurModics Signs Deal With Australian company Clinuvel Pharmaceuticals

(PBIO) Pressure Biosciences’ Technology on Display at Harvard Medical School Symposium

vitalstocks — Tue, 25 May 2010 03:19:59 +0000

Harvard Medical School Symposium On Friday, May 21, 2010, Harvard Medical School will host a symposium on the applications of ultra-high pressure in biotechnology. The full-day program focusing on the use of cycled ultra-high pressure (pressure cycling technology, or “PCT”) should highlight significant advancements in diagnostic and therapeutic medicine. Presenters include fifteen of the world’s [...]

(PBIO) Pressure Biosciences’ Technology on Display at Harvard Medical School Symposium

(MYGN) Myriad Genetics – Bear of the Day

vitalstocks — Mon, 24 May 2010 04:26:33 +0000

Myriad Genetics Inc.’s (MYGN) third quarter fiscal 2010 earnings of $0.33 per share fell short of the Zacks Consensus Estimate by $0.05. The company had earned $0.38 per share in the year-ago period. Myriad Genetics spun off its therapeutics business in July 2009 to focus on molecular diagnostics going forward. Although the molecular diagnostics business [...]

(MYGN) Myriad Genetics – Bear of the Day

(AMAG) AMAG Pharmaceuticals Signs Deal With Japan-Based Takeda Pharmaceutical Company

vitalstocks — Tue, 06 Apr 2010 20:46:38 +0000

Recently, AMAG Pharmaceuticals Inc. (AMAG) and Japan-based Takeda Pharmaceutical Co. Ltd. entered into a license, development and commercialization deal related to AMAG’s Feraheme (ferumoxytol) injection for intravenous (IV) use across all potential indications for the drug. Feraheme is an intravenous iron-replacement therapy for fighting anemia in patients with chronic kidney disease (CKD). The drug can [...]

(AMAG) AMAG Pharmaceuticals Signs Deal With Japan-Based Takeda Pharmaceutical Company

(ABAX) Abaxis Analyst Maintains Neutral Rating

vitalstocks — Thu, 01 Apr 2010 21:48:30 +0000

We recently reiterated our ‘Neutral’ rating on Abaxis, Inc. (ABAX) with a target price of $28, based on a P/E of 34.1x our fiscal 2011 EPS estimate of 82 cents. Abaxis’ results for the third quarter fiscal 2010 were mixed. Earnings per share for the third quarter was 15 cents, below the Zacks Consensus Estimate [...]

(ABAX) Abaxis Analyst Maintains Neutral Rating

(BLUD) Immucor Third Quarter Earnings Meets Consensus Estimates

vitalstocks — Thu, 01 Apr 2010 16:39:52 +0000

Immucor Inc. (BLUD) announced third quarter 2010 (ending in Feb 2010) earnings per share (EPS) of 28 cents, in line with the Zacks Consensus Estimate and a penny higher than the year ago quarter. Net income for the quarter was $20.1 million, compared with $19.5 million for the same quarter in 2009. The company reported [...]

(BLUD) Immucor Third Quarter Earnings Meets Consensus Estimates

(NEOG) Neogen’s Earnings Inches Past Estimates

vitalstocks — Wed, 31 Mar 2010 20:48:41 +0000

Neogen Corp. (NEOG) posted fiscal 2010 third-quarter results on Monday. The company’s net income recorded a strong growth of 37.5% to $3.9 million, or 17 cents per share from $2.8 million, or 12 cents per share in the year-ago period. The result also squeezed past the Zacks Consensus Estimate of 16 cents and was primarily [...]

(NEOG) Neogen’s Earnings Inches Past Estimates

(BLUD) Immucor Third Quarter 2010 Earnings Preview

vitalstocks — Mon, 29 Mar 2010 21:21:09 +0000

Immucor (BLUD) is scheduled to report its third quarter fiscal 2010 results on March 31, 2010. The Zacks Consensus Estimate for the quarter is pegged at a profit of 28 cents. Going by past trends, Immucor has surpassed expectations in the past four quarters. The company had a positive surprise of 20% and 7.69% in [...]

(BLUD) Immucor Third Quarter 2010 Earnings Preview

(SRDX) SurModics Analysts Upgrades the Stock to Neutral

vitalstocks — Sat, 27 Mar 2010 21:12:18 +0000

We have recently upgraded our recommendation on SurModics (SRDX) to Neutral. During the first quarter of 2010, the company’s earnings per share (EPS) came in at 24 cents, surpassing the Zacks Consensus Estimate by 5 cents. Although revenues of $21 million were down 26% from the year-ago period, it was primarily due to the termination [...]

(SRDX) SurModics Analysts Upgrades the Stock to Neutral

(VIVO) Meridian Bioscience Slashes Outlook For 2010

vitalstocks — Fri, 19 Mar 2010 22:14:47 +0000

Life science company, Meridian Bioscience, Inc. (VIVO), recently slashed its outlook for fiscal 2010 (ending Sep 30, 2010) mainly due to a weaker-than-expected H1N1 season and lower C. difficile product revenues. The company now expects net sales in the range of $145 million – $153 million in fiscal 2010, down from the earlier guidance of [...]

(VIVO) Meridian Bioscience Slashes Outlook For 2010

(AMAG) AMAG Pharmaceuticals Reports Narrower Fourth Quarter Loss

vitalstocks — Wed, 03 Mar 2010 23:47:08 +0000

AMAG Pharmaceuticals Inc. (AMAG) reported a fourth-quarter fiscal 2009 net loss of $18.4 million, or $1.07 per share, which was lower than the year-ago loss of $21.8 million, or $1.28. The Zacks Consensus Estimate for the reported quarter was a loss of $1.08. The lower loss in the quarter was attributable to higher revenues following [...]

(AMAG) AMAG Pharmaceuticals Reports Narrower Fourth Quarter Loss

(MYGN) Myriad Surpasses Consensus Estimates

vitalstocks — Thu, 04 Feb 2010 22:59:07 +0000

Myriad Genetics Inc. (MYGN) reported second quarter fiscal 2010 earnings of 36 cents per share, two cents above the Zacks Consensus Estimate. The company had earned 22 cents in the year-ago period. The year-ago earnings were inclusive of a loss of $15.6 million from discontinued operations pertaining to Myriad’s former research and pharmaceutical businesses. Detailed [...]

(MYGN) Myriad Surpasses Consensus Estimates

(ABAX) Abaxis Thurd Quarter 2010 Report Misses Estimates

vitalstocks — Mon, 01 Feb 2010 18:06:33 +0000

Abaxis, Inc. (ABAX) reported third quarter fiscal 2010 earnings per share of 15 cents, missing the Zacks Consensus Estimate of 17 cents. However, earnings in the year-ago quarter were 15 cents. Sales Total revenues in the third quarter increased 15% year over year to $31.0 million, fueled by higher instrument unit sales. Revenues from instrument [...]

(ABAX) Abaxis Thurd Quarter 2010 Report Misses Estimates

(SRDX) SurModics Earnings Report Beats Expectations

vitalstocks — Sat, 30 Jan 2010 01:15:15 +0000

SurModics (SRDX) reported first quarter fiscal 2010 earnings per share (EPS) of 11 cents, down from $1.53 in the year ago period. However, after adjustments, the EPS of 24 cents surpassed the Zacks Consensus Estimate by 5 cents. The company reported revenues of $17.4 million, down 72.5% from the corresponding period last year. The primary [...]

(SRDX) SurModics Earnings Report Beats Expectations

(VIVO) Meridian Bioscience Misses Expectations by a Penny

vitalstocks — Sat, 23 Jan 2010 21:29:26 +0000

Recently, Meridian Bioscience Inc. (VIVO) reported results for the first quarter of fiscal 2010. The company earned 22 cents per share in the quarter which fell short of the Zacks Consensus Estimate by a penny. Meridian Bioscience earned 20 cents per share in the year-ago quarter. Net sales for the quarter came in at $42.45 [...]

(VIVO) Meridian Bioscience Misses Expectations by a Penny

(ABAX) Abaxis Receives FDA Approval

vitalstocks — Sat, 23 Jan 2010 21:14:27 +0000

Abaxis, Inc. (ABAX) recently received the U.S. Food and Drug Administration (FDA) approval to market its new C-Reactive Protein (CRP) assay in the United States. The new C-Reactive Protein assay is used by healthcare professionals in conjunction with Abaxis’ Piccolo Xpress point-of-care analyzer to conduct on-site chemistry analysis for conditions like infections, inflammatory diseases, tissue [...]

(ABAX) Abaxis Receives FDA Approval

(AMAG) AMAG Pharmaceuticals Guides on Feraheme

vitalstocks — Tue, 12 Jan 2010 23:55:23 +0000

Recently, AMAG Pharmaceuticals Inc. (AMAG) stated that it expects net revenues between $12 and $13 million from its lead anti-anemia injectable product Feraheme for the fourth quarter of fiscal 2009 (ended December 31). AMAG had launched the Feraheme (ferumoxytol) injection in the United States on July 13, 2009. It is an intravenous iron replacement therapy [...]

(AMAG) AMAG Pharmaceuticals Guides on Feraheme

(BLUD) Immucor Beats Earnings Estimates

vitalstocks — Fri, 08 Jan 2010 20:34:17 +0000

Immucor (BLUD) announced second quarter 2010 earnings per share of 28 cents, which was better than the Zacks Consensus Estimate of 26 cents and the year-ago quarter’s 24 cents. Net income for the quarter was $19.7 million, compared with $17.3 million for the same quarter last year. The company reported $82.6 million in revenues, an [...]

(BLUD) Immucor Beats Earnings Estimates

(ABAX) Abaxis Launches New Bird Flu Test Product

vitalstocks — Wed, 30 Dec 2009 01:07:05 +0000

Abaxis, Inc. (ABAX) reported that it has launched its first product, a rapid Avian Influenza Antigen Test, in the production animal diagnostics market. Avian Influenza Antigen Test is a disposable and USDA-licensed test for Avian Influenza Type A nucleoprotein antigen in chickens, turkeys and ducks. Abaxis has worldwide rights to market this product globally. Avian [...]

(ABAX) Abaxis Launches New Bird Flu Test Product

(NEOG) Neogen Beats Earnings Expectations by a Penny

vitalstocks — Wed, 23 Dec 2009 01:01:12 +0000

Neogen Corp. (NEOG) recently posted fiscal second quarter results. The company’s GAAP net income grew 18% to $4.6 million, compared to $3.9 million in the year-ago period. Adjusting for a 3-for-2 stock split effective Dec 15, earnings per share came in at 20 cents per share, which edged past the Zacks Consensus Estimate by a [...]

(NEOG) Neogen Beats Earnings Expectations by a Penny

(MYGN) Myriad Genetics Upgraded to Neutral

vitalstocks — Thu, 17 Dec 2009 18:42:24 +0000

We have upgraded Myriad Genetics (MYGN) to Neutral from Underperform based on the impressive performance of its molecular diagnostics business. Effective July 1, 2009, the company spun off its therapeutics business to focus on molecular diagnostics. We believe that the de-risking strategy to separate the profitable predictive medicine business from the higher risk drug development [...]

(MYGN) Myriad Genetics Upgraded to Neutral

(MYGN) Myriad Genetics – Bear of the Day

vitalstocks — Mon, 16 Nov 2009 18:22:04 +0000

Myriad Genetics Inc. (MYGN) reported first quarter fiscal 2010 earnings of 31 cents per share, which was below the Zacks Consensus Estimate by a penny. The company had earned 25 cents per share in the year-ago period. Myriad Genetics spun off its therapeutics business in July 2009 to focus on molecular diagnostics going forward. Although [...]

(MYGN) Myriad Genetics – Bear of the Day

(MYGN) Myriad Genetics Inc Misses Forecasts by a Penny

vitalstocks — Mon, 09 Nov 2009 03:23:45 +0000

Myriad Genetics Inc. (MYGN) reported fiscal first-quarter earnings of 31 cents per share, a penny behind the Zacks Consensus Estimate. The company had earned 25 cents in the year-ago period. Molecular diagnostic revenues for the quarter came in at $85.12 million as against $69.97 million in the prior-year quarter, a 21.6% increase. The improvement was [...]

(MYGN) Myriad Genetics Inc Misses Forecasts by a Penny

(SRDX) SurModics Misses Earnings Estimates

vitalstocks — Sun, 08 Nov 2009 00:33:28 +0000

SurModics’ (SRDX) fourth-quarter earnings per share came in at 18 cents, below the Zacks Consensus Estimate of 20 cents. The company reported revenues of $19.2 million, down 17% compared to the year ago period. In addition to quarterly results, SurModics came out with fiscal year 2009 results. The company recorded revenues of $121.5 million in [...]

(SRDX) SurModics Misses Earnings Estimates

(ABAX) Abaxis Earnings Report Lags Consensus Estimates

vitalstocks — Wed, 28 Oct 2009 22:13:31 +0000

Abaxis Inc. (ABAX) reported second quarter fiscal 2010 earnings per share of 14 cents, lower than the Zacks Consensus Estimate of 17 cents and the year-ago earnings of 15 cents. Total revenues for the reported quarter were $30.3 million, logging a growth of 9% year over year. Growth was driven by strong medical and veterinary [...]

(ABAX) Abaxis Earnings Report Lags Consensus Estimates

(SRDX) Surmodics Inks Licensing Deal With Roche

vitalstocks — Fri, 09 Oct 2009 17:44:30 +0000

On Tuesday, SurModics Inc. (SRDX) announced that it licensed its drug delivery technology to Roche (RHHBY) and its wholly owned subsidiary, Genentech. Drug delivery technologies create and support site specific drug delivery polymers and coating technologies for use in drug/device combination products in chosen markets. Under the terms of the agreement, SurModics is entitled to [...]

(SRDX) Surmodics Inks Licensing Deal With Roche

(BLUD) Immucor Beats Estimates – Reaffirmed Fiscal 2010 Revenue and Earnings Guidance

vitalstocks — Tue, 06 Oct 2009 18:41:28 +0000

Recently, Immucor (BLUD) announced its first quarter (ending August 2009) 2010 earnings of 30 cents, which was better than the Zacks Consensus Estimate of 25 cents and the year ago quarter’s earnings of 28 cents. Net income in the quarter was $21.3 million, compared with $20.0 million for the same quarter last year. The company [...]

(BLUD) Immucor Beats Estimates – Reaffirmed Fiscal 2010 Revenue and Earnings Guidance

(ISTA) ISTA Pharmaceuticals Eye Drug Gets FDA Approval

vitalstocks — Wed, 09 Sep 2009 22:24:00 +0000

Yesterday, ISTA Pharmaceuticals Inc. (ISTA) announced that the U.S. Food and Drug Administration (FDA) approved its drug candidate, Bepreve, for the treatment of ocular itching associated with allergic conjunctivitis in patients two years and above. The drug is approved as a twice-daily prescription eye drop treatment. ISTA filed the New Drug Application for the drug [...]

(ISTA) ISTA Pharmaceuticals Eye Drug Gets FDA Approval

(ISTA) ISTA Pharmaceuticals’s Eye Drug Shows Success

vitalstocks — Thu, 27 Aug 2009 19:51:20 +0000

ISTA Pharmaceuticals Inc. (ISTA) yesterday announced that its once-per-day eye drug Xibrom QD displayed successful results in a late-stage study. The multi-center, randomized, double-masked, parallel-group study included 299 subjects who underwent cataract operation in one eye. ISTA revealed that Xibrom QD eye drops were significantly better than placebo at curing eye inflammation 15 days post [...]

(ISTA) ISTA Pharmaceuticals’s Eye Drug Shows Success

(MYGN) Myriad Reports Strong Earnings of 37 Cents vs. 23 Cents Estimate

vitalstocks — Wed, 26 Aug 2009 16:09:50 +0000

Yesterday, Myriad Genetics Inc. (MYGN) reported fourth quarter earnings of 37 cents per share from continuing operations. This was well above the Zacks Consensus Estimate of 23 cents. For fiscal year 2009, the company earned $1.38 per share from continuing operations. Molecular Diagnostic Revenues for the quarter came in at $86.1 million, versus $64.7 million [...]

(MYGN) Myriad Reports Strong Earnings of 37 Cents vs. 23 Cents Estimate